MedTrace Logo

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

NCT02856919 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2017-04-06

No results posted yet for this study

Summary

This study evaluates the efficacy of Mirvaso® in the treatment of chronic persistent vascular facial erythema, after 4 weeks of treatment, by the Clinician erythema assessment.

Conditions

  • Chronic Persistent Vascular Facial Erythema

Interventions

DRUG

brimonidine tartrate

Mirvaso® gel (5 mg/g brimonidine tartrate)

Sponsors & Collaborators

  • Eurotrials Brasil Consultores Cientificos Ltda

    collaborator INDUSTRY

  • Galderma Brasil Ltda.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-13
Primary Completion
2017-02-08
Completion
2017-02-08

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02856919 on ClinicalTrials.gov